直接口服抗凝剂在老年非瓣膜性房颤抗凝治疗有效性与安全性方面的最新进展
Recent Advances in the Effectiveness and Safety of Direct Oral Anticoagulation in Elderly Non-Valvular Atrial Fibrillation
摘要: 年龄是心房颤动的独立危险因素，且老年非瓣膜性房颤患者卒中发病率高。评估老年非瓣膜性房颤患者抗凝治疗的有效性及安全性、制定个体化抗凝治疗方案，均是临床工作的重点。近年来的研究表明，直接口服抗凝剂在有效性及安全性方面均优于华法林。不同的直接口服抗凝剂对比，阿哌沙班在有效性及安全性方面优于达比加群酯和利伐沙班。
Abstract: A high incidence of stroke in elderly patients with non-valvular AF, age is an independent risk factor for atrial fibrillation. Evaluating the effectiveness and safety of anticoagulant therapy and making individualized anticoagulation treatment plan are the focus of clinical work. Recent studies have shown that direct oral anticoagulants were superior to warfarin in terms of effectiveness and safety. By comparing different direct oral anticoagulants, apixaban outperformed dabigatran and rivaroxaban.
文章引用：钟少正, 袁忠明. 直接口服抗凝剂在老年非瓣膜性房颤抗凝治疗有效性与安全性方面的最新进展[J]. 临床医学进展, 2022, 12(12): 11491-11496. https://doi.org/10.12677/ACM.2022.1212656

参考文献

[1] Hindricks, G., Potpara, T., Dagres, N., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal, 42, 373-498. [Google Scholar] [CrossRef] [PubMed]
[2] 心房颤动基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2020, 19(6): 465-473.
[3] 中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动: 目前的认识和治疗建议(2021) [J]. 中华心律失常学杂志, 2022, 26(1): 15-88.
[4] Macle, L., Cairns, J., Leblanc, K., et al. (2016) 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 32, 1170-1185. [Google Scholar] [CrossRef] [PubMed]
[5] Chang, S.H., Chou, I.J., Yeh, Y.H., et al. (2017) Association be-tween Use of Non-Vitamin K Oral Anticoagulants with and without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA, 318, 1250-1259. [Google Scholar] [CrossRef] [PubMed]
[6] January, C.T., Wann, L.S., Calkins, H., et al. (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm, 16, e66-e93. [Google Scholar] [CrossRef] [PubMed]
[7] Leyva, F. and Plummer, C.J. (2015) National Institute for Health and Care Excellence 2014 Guidance on Cardiac Implantable Electronic Devices: Health Economics Reloaded. Europace, 17, 339-342. [Google Scholar] [CrossRef] [PubMed]
[8] Chong, D.T. andreotti, F., Verhamme, P., et al. (2021) Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. European Cardiology, 16, e23. [Google Scholar] [CrossRef] [PubMed]
[9] Proietti, M., Rivera-Caravaca, J.M., Esteve-Pastor, M.A., et al. (2018) Predicting Bleeding Events in Anticoagulated Patients with Atrial Fibrillation: A Comparison between the HAS-BLED and GARFIELD-AF Bleeding Scores. Journal of the American Heart Association, 7, e009766. [Google Scholar] [CrossRef] 
[10] Wastesson, J.W., Morin, L., Tan, E.C.K., et al. (2018) An Update on the Clinical Consequences of Polypharmacy in Older Adults: A Narrative Review. Expert Opinion on Drug Safety, 17, 1185-1196. [Google Scholar] [CrossRef] [PubMed]
[11] Trevisan, M., Hjemdahl, P., Clase, C.M., et al. (2022) Cardiorenal Outcomes among Patients with Atrial Fibrillation Treated with Oral Anticoagulants. American Journal of Kidney Diseases. [Google Scholar] [CrossRef] [PubMed]
[12] Durand, M., Schnitzer, M.E., Pang, M., et al. (2020) Comparative Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation: A Canadian Multicentre Observational Cohort Study. CMAJ Open, 8, E877-E886. [Google Scholar] [CrossRef] [PubMed]
[13] Carrier, M., Khorana, A.A., Zwicker, J., et al. (2013) Management of Challenging Cases of Patients with Cancer-Associated Thrombosis Including Recurrent Thrombosis and Bleeding: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 11, 1760-1765. [Google Scholar] [CrossRef] [PubMed]
[14] James, P.D., Connell, N.T., Ameer, B., et al. (2021) ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis of Von Willebrand Disease. Blood Advances, 5, 280-300. [Google Scholar] [CrossRef] [PubMed]
[15] Okumura, K., Akao, M., Yoshida, T., et al. (2020) Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. The New England Journal of Medicine, 383, 1735-1745. [Google Scholar] [CrossRef] 
[16] Potter, A.S., Patel, A., Khawaja, M., et al. (2022) Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients with Active Cancer. JACC: CardioOncology, 4, 341-350. [Google Scholar] [CrossRef] [PubMed]
[17] Beier, L., Lu, S., Franca, L.R., et al. (2022) Evolution of An-tithrombotic Therapy for Patients with Atrial Fibrillation: The Prospective Global GLORIA-AF Registry Program. PLOS ONE, 17, e0274237. [Google Scholar] [CrossRef] [PubMed]
[18] Lip, G.Y.H., Keshishian, A., Li, X., et al. (2018) Effectiveness and Safety of Oral Anticoagulants among Nonvalvular Atrial Fibrillation Patients. Stroke, 49, 2933-2944. [Google Scholar] [CrossRef] 
[19] Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. (2014) Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. The Lancet, 383, 955-962. [Google Scholar] [CrossRef] 
[20] Graham, D.J., Baro, E., Zhang, R., et al. (2019) Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. The American Journal of Medicine, 132, 596-604e11. [Google Scholar] [CrossRef] [PubMed]
[21] Pan, K.L., Singer, D.E., Ovbiagele, B., et al. (2017) Effects of Non-Vitamin K Antagonist Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 6, e005835. [Google Scholar] [CrossRef] 
[22] Sun, B., Chen, R.R., Gao, C., et al. (2022) Comparison of Out-comes between Novel Oral Anticoagulants and Warfarin Monotherapy in Patients with Left Atrial Appendage Closure: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article ID: 1023941. [Google Scholar] [CrossRef] [PubMed]
[23] Mikami, T., Hirabayashi, K., Okawa, K., et al. (2022) Laboratory Test Predictors for Major Bleeding in Elderly (>/= 80 Years) Patients with Nonvalvular Atrial Fibrillation Treated with Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial. Journal of the American Heart Association, 11, e024970. [Google Scholar] [CrossRef] 
[24] Bielecka, B., Gorczyca-Glowacka, I. and Wozakowska-Kaplon, B. (2022) Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs. International Journal of Environmental Research and Public Health, 19, Article No. 11938. [Google Scholar] [CrossRef] [PubMed]

为你推荐